Production (Stage)
DexCom, Inc.
DXCM
$84.51
-$0.32-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.15B | 4.03B | 3.95B | 3.93B | 3.80B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.15B | 4.03B | 3.95B | 3.93B | 3.80B |
| Cost of Revenue | 1.68B | 1.59B | 1.52B | 1.47B | 1.41B |
| Gross Profit | 2.47B | 2.44B | 2.44B | 2.47B | 2.39B |
| SG&A Expenses | 1.28B | 1.29B | 1.26B | 1.24B | 1.21B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.52B | 3.43B | 3.33B | 3.25B | 3.15B |
| Operating Income | 632.60M | 600.00M | 628.00M | 681.50M | 651.60M |
| Income Before Tax | 730.80M | 709.00M | 743.90M | 806.90M | 778.40M |
| Income Tax Expenses | 195.60M | 132.80M | 63.10M | 140.00M | 139.10M |
| Earnings from Continuing Operations | 535.20 | 576.20 | 680.80 | 666.90 | 639.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 535.20M | 576.20M | 680.80M | 666.90M | 639.30M |
| EBIT | 632.60M | 600.00M | 628.00M | 681.50M | 651.60M |
| EBITDA | 857.80M | 817.70M | 840.40M | 886.80M | 848.50M |
| EPS Basic | 1.36 | 1.46 | 1.74 | 1.71 | 1.65 |
| Normalized Basic EPS | 1.16 | 1.13 | 1.19 | 1.30 | 1.26 |
| EPS Diluted | 1.33 | 1.42 | 1.67 | 1.62 | 1.55 |
| Normalized Diluted EPS | 1.11 | 1.08 | 1.12 | 1.20 | 1.15 |
| Average Basic Shares Outstanding | 1.58B | 1.57B | 1.57B | 1.56B | 1.55B |
| Average Diluted Shares Outstanding | 1.64B | 1.65B | 1.66B | 1.68B | 1.69B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |